How India Exports Moov to the World

As of March 2026, "Moov" (HS Code: 30049011) has not been approved by the U.S. Food and Drug Administration (FDA) under an Abbreviated New Drug Application (ANDA). A search of the FDA's Orange Book, which lists approved drug products, does not show any entries for "Moov." Consequently, "Moov" is not authorized for marketing in the United States.

Regarding import alerts, the FDA issues these to prevent the entry of products that appear to violate FDA laws and regulations. As of March 2026, "Moov" is not listed on any FDA import alerts, indicating no specific enforcement actions against this product. However, the absence of an import alert does not equate to approval or authorization for marketing in the U.S. Importers must ensure compliance with all FDA regulations, including obtaining necessary approvals before marketing any pharmaceutical product.

In the European Union (EU) and the United Kingdom (UK), pharmaceutical products require marketing authorization from the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. As of March 2026, "Moov" does not hold marketing authorization from either the EMA or the MHRA. This means "Moov" is not legally available for sale or distribution within these jurisdictions.

Compliance with Good Manufacturing Practice (GMP) standards is mandatory for pharmaceutical products in the EU and UK. Manufacturers must adhere to these standards to ensure product quality and safety. Without marketing authorization, "Moov" cannot be legally manufactured or distributed in these regions.

The World Health Organization (WHO) maintains the Model List of Essential Medicines, identifying medications considered essential for basic healthcare systems. As of the 22nd edition published in 2021, "Moov" is not included in this list. Additionally, "Moov" has not undergone the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products.

Pharmaceutical products are expected to comply with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality and consistency of pharmaceutical products.

In India, the Central Drugs Standard Control Organisation (CDSCO) classifies drugs into schedules under the Drugs and Cosmetics Act. "Moov" is classified as an over-the-counter (OTC) product, allowing it to be sold without a prescription. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines under the Drug Price Control Order (DPCO). As of March 2026, "Moov" is not listed under the DPCO, indicating no price ceiling is imposed on this product.

For exporting pharmaceutical products, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT). This certificate ensures that the product complies with the regulatory requirements of the importing country.

As of March 2026, "Moov" is not protected by any active patents, allowing for generic competition. This lack of patent protection enables multiple manufacturers to produce and market "Moov," contributing to its widespread availability and competitive pricing.

In June 2025, the Indian Ministry of Health and Family Welfare implemented new guidelines for the export of over-the-counter (OTC) pharmaceutical products, including "Moov." These guidelines aim to streamline the export process and ensure compliance with international standards.

In September 2025, the Directorate General of Foreign Trade (DGFT) introduced an online portal for the issuance of No Objection Certificates (NOCs) required for pharmaceutical exports. This digital initiative is designed to expedite the approval process and enhance transparency.

In December 2025, the Central Drugs Standard Control Organisation (CDSCO) updated the Indian Pharmacopoeia to include revised standards for topical analgesic products. Manufacturers of products like "Moov" are required to comply with these updated standards to ensure product quality and safety.

In February 2026, the National Pharmaceutical Pricing Authority (NPPA) conducted a review of the pricing of non-scheduled drugs, including OTC products. While "Moov" remains outside the purview of price control under the DPCO, the NPPA emphasized the importance of fair pricing practices in the pharmaceutical industry.

In March 2026, the World Health Organization (WHO) released a report highlighting the significance of adhering to international pharmacopoeia standards for OTC products. The report underscores the need for manufacturers to ensure their products meet these standards to facilitate global trade and maintain consumer trust.

India's pharmaceutical industry, including the production of "Moov," heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these essential components are sourced from China, creating a significant dependency. This reliance exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or quality control issues.

In response, the Indian government has initiated measures to reduce this dependency. In October 2024, two greenfield plants were inaugurated under the Production Linked Incentive (PLI) scheme for bulk drugs, aiming to manufacture critical molecules like Penicillin G, 6-APA, and Clavulanic Acid. These efforts are projected to halve India's import dependence on key pharmaceutical ingredients.

Our proprietary trade data indicates a high supplier concentration for "Moov" exports from India. The top five exporters account for 80.5% of the total export value, with RECKITT BENCKISER HEALTHCARE INDIA PRIVATE LIMITED leading at 22.4%. Such concentration poses a single-source risk, where disruptions affecting these key suppliers could significantly impact the supply chain.

The PLI scheme, launched in October 2024, aims to bolster domestic production of APIs and KSMs, thereby reducing reliance on a limited number of suppliers. However, the effectiveness of this initiative in diversifying the supplier base and mitigating single-source risks remains to be fully realized.

Recent geopolitical events have introduced substantial risks to global supply chains. In February 2026, escalating conflicts led to the blockade of the Strait of Hormuz, a critical chokepoint through which approximately 20% of global oil passes. This blockade has disrupted maritime traffic, leading to increased shipping costs and delays.

Additionally, tensions in the Red Sea and the Bab al-Mandab Strait have further complicated shipping routes, forcing vessels to reroute around the Cape of Good Hope, adding significant transit times and costs. These disruptions have cascading effects on the pharmaceutical supply chain, potentially delaying the export of "Moov" and increasing operational costs.

To address the identified risks, the following actionable steps are recommended:

• Diversify Supplier Base: Expand the network of API and KSM suppliers beyond China to reduce dependency and enhance supply chain resilience.

• Strengthen Domestic Production: Accelerate the implementation of the PLI scheme and similar initiatives to boost local manufacturing capabilities for critical pharmaceutical ingredients.

• Enhance Supplier Audits: Implement rigorous quality control and compliance audits for existing and new suppliers to ensure consistent product quality and regulatory adherence.

• Develop Contingency Plans: Establish alternative shipping routes and logistics strategies to mitigate the impact of geopolitical disruptions on transportation.

• Monitor Geopolitical Developments: Continuously assess global political landscapes to anticipate and proactively address potential supply chain disruptions.

RISK_LEVEL: HIGH